Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBIT (2016 - 2025)

Historic EBIT for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $5.3 million.

  • Lifecore Biomedical, Inc. \De\'s EBIT rose 14788.27% to $5.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$17.2 million, marking a year-over-year decrease of 9501.3%. This contributed to the annual value of -$17.2 million for FY2025, which is 9499.1% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its EBIT stood at $5.3 million for Q2 2025, which was up 14788.27% from -$9.0 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s EBIT peaked at $5.3 million during Q2 2025, and registered a low of -$11.6 million during Q3 2024.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s EBIT had a median value of -$2.9 million in 2022 and averaged -$3.3 million.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s EBIT skyrocketed by 17394.21% in 2021, and later plummeted by 1330273.97% in 2022.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s EBIT stood at $3.7 million in 2021, then crashed by 245.04% to -$5.4 million in 2022, then surged by 72.29% to -$1.5 million in 2023, then plummeted by 32.1% to -$2.0 million in 2024, then surged by 371.92% to $5.3 million in 2025.
  • Its EBIT was $5.3 million in Q2 2025, compared to -$9.0 million in Q1 2025 and -$2.0 million in Q4 2024.